scholarly journals BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies

Haemophilia ◽  
2018 ◽  
Vol 24 (5) ◽  
pp. 733-740 ◽  
Author(s):  
A. Shah ◽  
T. Coyle ◽  
S. Lalezari ◽  
K. Fischer ◽  
B. Kohlstaedde ◽  
...  
Keyword(s):  
Factor Viii ◽  
Clinical Studies ◽  
Half Life ◽  
Area Under The Curve ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Pharmacokinetic Assessment

scholarly journals Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A

Haemophilia ◽  
2016 ◽  
Vol 23 (2) ◽  
pp. 238-246 ◽  
Author(s):  
E. S. Mullins ◽  
O. Stasyshyn ◽  
M. T. Alvarez-Román ◽  
D. Osman ◽  
R. Liesner ◽  
...  
Keyword(s):  
Factor Viii ◽  
Half Life ◽  
Full Length ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Severe Haemophilia

Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A

Haemophilia ◽  
2018 ◽  
Vol 24 (4) ◽  
pp. e280-e283
Author(s):  
I. C. L. Kremer Hovinga ◽  
R. E. G. Schutgens ◽  
P. R. van der Valk ◽  
L. F. D. van Vulpen ◽  
E. P. Mauser-Bunschoten ◽  
...  
Keyword(s):  
Factor Viii ◽  
Continuous Infusion ◽  
Half Life ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Life Factor

Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting

2008 ◽  
Vol 99 (01) ◽  
pp. 52-58 ◽  
Author(s):  
Elena Santagostino ◽  
Albert Faradji ◽  
Alfonso Iorio ◽  
Jan van der Meer ◽  
Jørgen Ingerslev ◽  
...  
Keyword(s):  
Observational Study ◽  
Factor Viii ◽  
De Novo ◽  
Observation Time ◽  
Full Length ◽  
Recombinant Factor Viii ◽  
Phase Iii ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Safety And Efficacy

SummaryThe safety of full-length sucrose-formulated recombinant factor VIII (rFVIII-FS; KOGENATE® FS) for up to 24 months of use was evaluated in a postmarketing observational study in Europe. Long-term safety and efficacy data were available for 212 patients with severe haemophilia A, including 13 previously untreated patients (PUPs) and 12 patients with 1–19 exposure days (EDs). Patients accumulated a mean (± SD) of 187 (121) EDs to rFVIII-FS and received a total of 39,627 infusions, mainly for prophylaxis and for the treatment of 4,283 spontaneous or trauma-related bleeds during an average observation time of 710 (136) days. Of these bleeding episodes, 85.4% were successfully treated with one or two infusions of rFVIII-FS. Haemostasis was also evaluated during 46 minor to major surgical pro- cedures, and the response to infusion was “excellent” or “good” in all cases. FVIII inhibitor formation was observed in six patients (two de novo; four persistent or recurrent). The de novo cases represent 8.0% (2 of 25) of patients who reported 0–19 previous EDs at study entry. Four of the five patients who reported possible drug-related adverse effects developed inhibitors. The results of this observational study demonstrate the efficacy and safety of rFVIII-FS during normal clinical use in the treatment of patients with severe haemophilia A. Furthermore, these findings are consistent with those of previous phase III clinical studies with rFVIII-FS, particularly with regard to its efficacy and low incidence of inhibitor formation.

scholarly journals Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis

Haemophilia ◽  
2018 ◽  
Vol 24 (2) ◽  
pp. 245-252 ◽  
Author(s):  
M. Carcao ◽  
A. Shapiro ◽  
J. M. Staber ◽  
N. Hwang ◽  
C. Druzgal ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Factor Viii ◽  
Retrospective Analysis ◽  
Immune Tolerance ◽  
Tolerance Induction ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Immune Tolerance Induction ◽  
Fc Fusion Protein

scholarly journals SHP656, a polysialylated recombinant factor VIII (PSA‐rFVIII): First‐in‐human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

Haemophilia ◽  
2019 ◽  
Vol 26 (1) ◽  
pp. 47-55 ◽  
Author(s):  
Andreas Tiede ◽  
Geoffrey Allen ◽  
Alexander Bauer ◽  
Pratima Chowdary ◽  
Peter Collins ◽  
...  
Keyword(s):  
Factor Viii ◽  
Human Study ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Severe Haemophilia

scholarly journals PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A

Haemophilia ◽  
2020 ◽  
Vol 26 (3) ◽  
Author(s):  
Elena Santagostino ◽  
Gili Kenet ◽  
Kathelijn Fischer ◽  
Tina Biss ◽  
Sanjay Ahuja ◽  
...  
Keyword(s):  
Factor Viii ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Safety And Efficacy ◽  
Previously Treated

IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A

Haemophilia ◽  
2007 ◽  
Vol 13 (1) ◽  
pp. 104-105 ◽  
Author(s):  
J. G. KADAR ◽  
J. SCHUSTER ◽  
N. HUNZELMANN
Keyword(s):  
Factor Viii ◽  
Anaphylactic Reaction ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Ige Mediated

scholarly journals Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)

Haemophilia ◽  
2019 ◽  
Vol 25 (3) ◽  
pp. 373-381 ◽  
Author(s):  
Nicola Curry ◽  
Canan Albayrak ◽  
Miguel Escobar ◽  
Pål Andre Holme ◽  
Susan Kearney ◽  
...  
Keyword(s):  
Factor Viii ◽  
Recombinant Factor Viii ◽  
Phase Iii ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Phase Iii Trial ◽  
Safety And Efficacy
Sign in / Sign up

Export Citation Format

Share Document